Price Action to Note: Today Allergan plc Ordinary Shares Stock Reaches Yearly Low

Price Action to Note: Today Allergan plc Ordinary Shares Stock Reaches Yearly Low

The stock of Allergan plc Ordinary Shares (NYSE:AGN) hit a new 52-week low and has $180.52 target or 5.00% below today’s $190.02 share price. The 7 months bearish chart indicates high risk for the $70.83B company. The 1-year low was reported on Nov, 23 by Barchart.com. If the $180.52 price target is reached, the company will be worth $3.54B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 621,203 shares traded hands. Allergan plc Ordinary Shares (NYSE:AGN) has declined 16.99% since April 21, 2016 and is downtrending. It has underperformed by 22.32% the S&P500.

Analysts await Allergan plc Ordinary Shares (NYSE:AGN) to report earnings on February, 27. They expect $3.74 EPS, up 9.68% or $0.33 from last year’s $3.41 per share. AGN’s profit will be $1.39 billion for 12.70 P/E if the $3.74 EPS becomes a reality. After $3.32 actual EPS reported by Allergan plc Ordinary Shares for the previous quarter, Wall Street now forecasts 12.65% EPS growth.

Allergan plc Ordinary Shares (NYSE:AGN) Ratings Coverage

Out of 18 analysts covering Allergan Inc. (NYSE:AGN), 14 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 78% are positive. $400 is the highest target while $232 is the lowest. The $296.47 average target is 56.02% above today’s ($190.02) stock price. Allergan Inc. has been the topic of 46 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Thursday, April 7 by Susquehanna. Deutsche Bank maintained the stock with “Buy” rating in Tuesday, August 9 report. TheStreet upgraded the stock to “Buy” rating in Wednesday, July 29 report. The firm has “Outperform” rating by Wells Fargo given on Friday, February 19. Mizuho maintained it with “Buy” rating and $299 target price in Tuesday, October 11 report. Mizuho maintained Allergan plc Ordinary Shares (NYSE:AGN) rating on Tuesday, November 1. Mizuho has “Buy” rating and $293.0 price target. The company was maintained on Tuesday, September 29 by Raymond James. The firm has “Buy” rating by Mizuho given on Tuesday, February 23. Morgan Stanley maintained Allergan plc Ordinary Shares (NYSE:AGN) on Thursday, November 3 with “Overweight” rating. The firm has “Buy” rating by Deutsche Bank given on Thursday, April 7.

According to Zacks Investment Research, “Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 4 in Q2 2016. Its up 3.54, from 0.46 in 2016Q1. The ratio improved, as 11 funds sold all Allergan plc Ordinary Shares shares owned while 2 reduced positions. 3 funds bought stakes while 3 increased positions. They now own 58,328 shares or 8.83% less from 63,978 shares in 2016Q1.
Armstrong Henry H Associates Incorporated accumulated 0.17% or 3,690 shares. Chartist Ca has invested 0% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Moreover, Mengis Cap Mngmt has 1.27% invested in Allergan plc Ordinary Shares (NYSE:AGN) for 6,210 shares. American Research has invested 0% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Dowling Yahnke Ltd Llc holds 0.06% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 2,145 shares. Grassi Investment Mngmt last reported 0.22% of its portfolio in the stock. Bartlett & Com Ltd Liability Corporation accumulated 494 shares or 0.01% of the stock. Frontier Investment Mgmt has 32,758 shares for 0.94% of their US portfolio. Mitchell Mcleod Pugh And Williams Incorporated owns 3,975 shares or 0.83% of their US portfolio. Marshwinds Advisory accumulated 0.1% or 927 shares. Connors Investor Serv has 1,000 shares for 0.04% of their US portfolio. Moreover, Gemmer Asset Limited Liability Company has 0.02% invested in Allergan plc Ordinary Shares (NYSE:AGN) for 127 shares.

More recent Allergan plc Ordinary Shares (NYSE:AGN) news were published by: Investorplace.com which released: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” on November 02, 2016. Also Investorplace.com published the news titled: “Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?” on September 20, 2016. Valuewalk.com‘s news article titled: “Allergan plc Ordinary Shares (AGN) Collapses On Treasury Ruling, Analysts React” with publication date: April 05, 2016 was also an interesting one.

AGN Company Profile

Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Firm is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company’s divisions are US Brands, US Medical Aesthetics and International Brands. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment